FDA approves Merck’s KEYTRUDA for unresectable or metastatic MSI-H or dMMR colorectal cancer

This article was originally published here

The approval is based on results from the Phase 3 KEYNOTE-177 trial, in which KEYTRUDA significantly reduced the risk of disease progression or death by 40% (HR=0.60 [95%

The post FDA approves Merck’s KEYTRUDA for unresectable or metastatic MSI-H or dMMR colorectal cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply